The firm will track the activity of the triplet broadly in AML patients, including in those with FLT3, NRAS, and TP53 mutations.
Pentixapharm said on Thursday it has begun treating patients in a Phase I/II trial of its radiopharmaceutical therapy Lu177-PentixaTher in adult patients with relapsed or refractory CXCR4-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback